triple glp 1 agonist 🎙️ NEW EPISODE: Retatrutide—The *Not licensed* Will this replace the current GLP-1 in the market. This triple receptor agonist (GIP/ GLP-1/glucagon) is showing unprecedented results in weight loss trials, outperforming current Bariatric (<20g net carbs & 5g or less Sugar) Flavor:The Summer Body Set One in eight adults

triple glp 1 agonist 🎙️ NEW EPISODE: Retatrutide—The *Not licensed* Will this replace the current GLP-1 in the market. This triple receptor agonist (GIP/ GLP-1/glucagon) is showing unprecedented results in weight loss trials, outperforming current Bariatric (<20g net carbs & 5g or less Sugar) Flavor:The Summer Body Set One in eight adults

One in eight adults have taken a glucagon-like peptide 1 (GLP-1) agonist to lose weight or to treat a comorbidity like type 2 diabetes or cardiovascular disease. And by some accounts, more

Cardiorenal Med

Bariatric (<20g net carbs & 5g or less Sugar)

Flavor:The Summer Body Set

Moreover, worsening glycemic control escalates the likelihood of AP (Cho et al., 2023)